Tuesday, February 21, 2017 1:03:53 PM
This PPS manipulation used to be bad news for CNAT because it made trial financing more and more dilutive.
The good news now is that there is no more dilution to come as the trials and commercialization are now (subject to NVS option exercise) fully funded but CNAT is also going to get $650M plus royaltoes that could go as high as 25-30% on net sales.
So Emricasan success will now only depend on its efficacy and safety, and the trials have given strong hints of efficacy. Moreover Novartis has deeply looked into it and willing to invest more than $1B just to get the drug approved.
So we can only thank MM for these prices, and I hope they will continue much longer, as they allow us to buy a stock that could be worth 1,000 times current PPS in 5 years time
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM